市場調查報告書

中性粒細胞減少症的全球市場-機會分析/行業預測(2020-2027):按治療/分佈渠道

Neutropenia Treatment Market by Treatment, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2020-2027

出版商 Allied Market Research 商品編碼 948602
出版日期 內容資訊 英文 210 Pages
商品交期: 2-3個工作天內
價格
中性粒細胞減少症的全球市場-機會分析/行業預測(2020-2027):按治療/分佈渠道 Neutropenia Treatment Market by Treatment, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2020-2027
出版日期: 2020年05月01日內容資訊: 英文 210 Pages
簡介

2019年,全球中性粒細胞減少症治療市場價值126.225億美元,預計到2027年將達到193.310億美元,在預測期內的複合年增長率為5.4。 % 是期待。由於癌症病例的發生率增加,預計對中性粒細胞減少症的治療需求在未來會顯著增長。領先公司建立新的中性粒細胞減少症治療藥物的研發活動也將在預測期內刺激需求。但是,中性粒細胞減少症的治療費用很高,嚴格的藥物批准規章制度可能會在預測期內阻礙市場增長。此外,從品牌藥物到低成本生物仿製藥的範式轉變有望為行業參與者提供豐厚的激勵。

該報告調查了全球中性粒細胞減少症治療市場,並提供了市場概況和動態,按細分市場/區域進行的市場規模分析和預測以及主要公司的概況。

第1章簡介

第2章執行摘要

第3章市場概述

  • 市場定義和範圍
  • 主要發現
    • 管道分析
    • 主要成功策略
    • 主要公司的定位
  • 決定全球中性粒細胞減少症治療市場的關鍵因素
  • 市場動態
    • 促進要因
      • 白血病患病率上升
      • 研發努力和新藥開發的快速增長
      • 從品牌藥物到生物仿製藥的徹底轉變為癌症的支持治療
    • 抑制因子
      • 中性粒細胞減少症的治療費用高
      • 嚴格的產品認證法規
    • 市場機會
      • 用於中性粒細胞減少症治療的可靠藥物管道
  • 中性粒細胞減少症的標準治療方法和推薦指南

第4章按治療分列的全球中性粒細胞減少症治療市場

  • 概述
    • 市場規模和預測
  • 菌落刺激因子(CSF)
    • 主要市場趨勢,增長因素,機遇
    • 市場規模和地區預測
    • 國家市場分析
  • 抗生素
  • 抗真菌劑
  • 抗病毒藥

第5章按分銷渠道劃分的全球中性粒細胞減少症治療市場

  • 概述
    • 市場規模和預測
  • 醫院藥房
    • 市場規模和地區預測
    • 國家市場分析
  • 零售藥房
  • 在線藥房

第6章按地區分列的全球中性粒細胞減少症治療市場

  • 概述
    • 市場規模和預測
  • 北美
    • 主要市場趨勢和機遇
    • 市場規模和治療預測
    • 市場規模和分銷渠道預測
    • 市場規模和國家預測
      • 美國
      • 美國採購/分銷渠道
      • 加拿大
      • 墨西哥
  • 歐洲
    • 主要市場趨勢和機遇
    • 市場規模和治療預測
    • 市場規模和分銷渠道預測
    • 市場規模和國家預測
      • 歐洲採購/分銷渠道
      • 德國
      • 法國
      • 英國
      • 意大利
      • 西班牙
      • 其他歐洲
  • 亞太地區
    • 主要市場趨勢和機遇
    • 市場規模和治療預測
    • 市場規模和分銷渠道預測
    • 市場規模和國家預測
      • 日本
      • 中國
      • 澳大利亞
      • 印度
      • 其他亞太地區
  • 拉丁美洲/中東/非洲
    • 主要市場趨勢和機遇
    • 市場規模和治療預測
    • 市場規模和分銷渠道預測
    • 市場規模和國家預測
      • 巴西
      • 沙特阿拉伯
      • 南非
      • 其他LAMEA

第7章公司簡介

  • AMGEN INC.
  • BEYONDSPRING INC.
  • CELLERANT THERAPEUTICS, INC.
  • KYOWA KIRIN
  • MYLAN N.V.
  • NOVARTIS AG
  • PARTNER THERAPEUTICS, INC.
  • PFIZER INC.
  • SPECTRUM PHARMACEUTICALS, INC.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • COHERUS BIOSCIENCES, INC.
目錄
Product Code: A06298

Title:
Neutropenia Treatment Market by Treatment (Colony-stimulating factors, Antibiotics, Antifungals, and Antivirals), and Distribution Channel (Hospital Pharmacies , Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2020-2027.

The global neutropenia treatment market was valued at $12,602.5 million in 2019, and is expected to reach $19,303.1 million by 2027, with a CAGR of 5.4% during the forecast period.

Neutropenia refers to reduced neutrophil count in the blood. Normal individuals have a neutrophil count in the blood ranging between 1,500 and 8,000 cells/cubic meter. When neutrophil count falls below the 1,500 cells/mm3 threshold, a patient is classified as neutropenic. Generally, neutrophils drop below normal level within after 7-12 days of cancer chemotherapy.

The demand for neutropenia therapy is projected to experience substantial growth in the future, owing to growth in incidences of cancer cases. Increase in R&D activities by key companies to establish new neutropenia therapies are also anticipated to fuel the demand during the forecast period. However, high cost of neutropenia care and strict drug approval rules and regulations are likely to hinder the market growth during the forecast period. In addition, paradigm transition from branded drugs to low-cost biosimilars is projected to provide industry players with remunerative incentives.

Depending on treatment, the market is categorized into colony-stimulating factors, antibiotics, antifungals, and antivirals. The colony-stimulating factors segment dominated the global market in 2019, and is anticipated to continue this trend during the forecast period. Rise in incidences of cancer cases and further increase in number of patients undergoing chemotherapy around the globe drives the growth of this treatment segment.

On the basis of distribution channel, the market is categorized into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies segment held a dominant portion in the market, accounting for about 40.6% share of the global neutropenia treatment market in 2019.

North America accounted for the largest share in the global neutropenia treatment market. Further, Asia-Pacific is expected to witness highest growth rate for the market throughout the forecast period. Increase in incidences of leukemia will drive the overall market during the forecast period. As, Europe is considered as the advanced biosimilar market as compared to non-European countries, high cost of the treatment of neutropenia is expected to restrict the growth of the market during the forecast period.

The major companies profiled in this report include Amgen, BeyondSpring, Kyowa Kirin, Cellerant Therapeutics, Mylan N.V., Novartis AG, Partner Therapeutics, Pfizer, Spectrum Pharmaceuticals and Teva Pharmaceutical Industries Ltd. Other players in neutropenia market (not profiled in the report) include Myelo Therapeutics, and Enzychem Lifesciences Corporation Samsung Medical Center.

KEY BENEFITS FOR STAKEHOLDERS

This report entails a detailed quantitative analysis along with the current neutropenia treatment trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessment.

The market forecast is studied from 2020 to 2027.

The market size and estimations are based on a comprehensive analysis of key developments in the industry.

A qualitative analysis based on innovative products facilitates strategic business planning.

The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.

KEY MARKET SEGMENTS

By Treatment

  • Colony-stimulating factors,
  • Antibiotics
  • Antifungals
  • Antivirals

By Distribution Channel

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • South Africa
  • Saudi Arabia
  • Rest of LAMEA
  • KEY MARKET PLAYERS
  • Amgen
  • BeyondSpring
  • Kyowa Kirin
  • Cellerant Therapeutics
  • Mylan N.V.
  • Novartis AG
  • Partner Therapeutics
  • Pfizer
  • Spectrum Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Coherus Biosciences

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools & models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Pipeline Analysis
    • 3.2.2.Top winning strategies
    • 3.2.3.Top player positioning
  • 3.3.Key forces shaping the global neutropenia treatment market
  • 3.4.Market dynamics
    • 3.4.1.Drivers
      • 3.4.1.1.Rise in prevalence of leukemia
      • 3.4.1.2.Surge in R&D efforts and development of new drugs
      • 3.4.1.3.Fundamental shift from branded drugs to biosimilars in cancer supportive treatment
    • 3.4.2.Restraints
      • 3.4.2.1.High cost of the treatment of neutropenia
      • 3.4.2.2.Stringent rules and regulations for product approvals
    • 3.4.3.Opportunity
      • 3.4.3.1.Robust drug pipeline for neutropenia treatment
  • 3.5.Standard of Care for Neutropenia treatment and recommended guidelines

CHAPTER 4:GLOBAL NEUTROPENIA TREATMENT MARKET, BY TREATMENT

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Colony-stimulating factors (CSFs)
    • 4.2.1.Key market trends, growth factors and opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market analysis, by country
  • 4.3.Antibiotics
    • 4.3.1.Key market trends, growth factors and opportunities
    • 4.3.2.Market size and forecast, by region
    • 4.3.3.Market analysis, by country
  • 4.4.Antifungals
    • 4.4.1.Key market trends, growth factors and opportunities
    • 4.4.2.Market size and forecast, by region
    • 4.4.3.Market analysis, by country
  • 4.5.Antivirals
    • 4.5.1.Key market trends, growth factors and opportunities
    • 4.5.2.Market size and forecast, by region
    • 4.5.3.Market analysis, by country

CHAPTER 5:GLOBAL NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Hospital Pharmacies
    • 5.2.1.Market size and forecast, by region
    • 5.2.2.Market analysis, by country
  • 5.3.Retail Pharmacies
    • 5.3.1.Market size and forecast, by region
    • 5.3.2.Market analysis, by country
  • 5.4.Online Pharmacies
    • 5.4.1.Market size and forecast, by region
    • 5.4.2.Market analysis, by country

CHAPTER 6:GLOBAL NEUTROPENIA TREATMENT MARKET, BY REGION

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.North America
    • 6.2.1.Key market trends and opportunities
    • 6.2.2.Market size and forecast, by treatment
    • 6.2.3.Market size and forecast, by distribution channel
    • 6.2.4.Market size and forecast, by country
      • 6.2.4.1.U.S.
      • 6.2.4.2.Purchasing/distribution channels in the U.S.
      • 6.2.4.2.1.U.S. market size and forecast, by treatment
      • 6.2.4.2.2.U.S. market size and forecast, by distribution channel
      • 6.2.4.3.Canada
      • 6.2.4.3.1.Canada market size and forecast, by treatment
      • 6.2.4.3.2.Canada market size and forecast, by distribution channel
      • 6.2.4.4.Mexico
      • 6.2.4.4.1.Mexico market size and forecast, by treatment
      • 6.2.4.4.2.Mexico market size and forecast, by distribution channel
  • 6.3.Europe
    • 6.3.1.Key market trends and opportunities
    • 6.3.2.Market size and forecast, by treatment
    • 6.3.3.Market size and forecast, by distribution channel
    • 6.3.4.Market size and forecast, by country
      • 6.3.4.1.Purchasing/distribution channels in the Europe
      • 6.3.4.2.Germany
      • 6.3.4.2.1.Germany market size and forecast, by treatment
      • 6.3.4.2.2.Germany market size and forecast, by distribution channel
      • 6.3.4.3.France
      • 6.3.4.3.1.France market size and forecast, by treatment
      • 6.3.4.3.2.France market size and forecast, by distribution channel
      • 6.3.4.4.UK
      • 6.3.4.4.1.UK market size and forecast, by treatment
      • 6.3.4.4.2.UK market size and forecast, by distribution channel
      • 6.3.4.5.Italy
      • 6.3.4.5.1.Italy market size and forecast, by treatment
      • 6.3.4.5.2.Italy market size and forecast, by distribution channel
      • 6.3.4.6.Spain
      • 6.3.4.6.1.Spain market size and forecast, by treatment
      • 6.3.4.6.2.Spain market size and forecast, by distribution channel
      • 6.3.4.7.Rest of Europe
      • 6.3.4.7.1.Rest of Europe market size and forecast, by treatment
      • 6.3.4.7.2.Rest of Europe market size and forecast, by distribution channel
  • 6.4.Asia-Pacific
    • 6.4.1.Key market trends and opportunities
    • 6.4.2.Market size and forecast, by treatment
    • 6.4.3.Market size and forecast, by distribution channel
    • 6.4.4.Market size and forecast, by country
      • 6.4.4.1.Japan
      • 6.4.4.1.1.Purchasing/distribution channels in the Japan
      • 6.4.4.1.2.Japan market size and forecast, by treatment
      • 6.4.4.1.3.Japan market size and forecast, by distribution channel
      • 6.4.4.2.China
      • 6.4.4.2.1.China market size and forecast, by treatment
      • 6.4.4.2.2.China market size and forecast, by distribution channel
      • 6.4.4.3.Australia
      • 6.4.4.3.1.Australia market size and forecast, by treatment
      • 6.4.4.3.2.Australia market size and forecast, by distribution channel
      • 6.4.4.4.India
      • 6.4.4.4.1.India market size and forecast, by treatment
      • 6.4.4.4.2.India market size and forecast, by distribution channel
      • 6.4.4.5.Rest of Asia-Pacific
      • 6.4.4.5.1.Rest of Asia-Pacific market size and forecast, by treatment
      • 6.4.4.5.2.Rest of Asia-Pacific market size and forecast, by distribution channel
  • 6.5.LAMEA
    • 6.5.1.Key market trends and opportunities
    • 6.5.2.Market size and forecast, by treatment
    • 6.5.3.Market size and forecast, by distribution channel
    • 6.5.4.Market size and forecast, by country
      • 6.5.4.1.Brazil
      • 6.5.4.1.1.Brazil market size and forecast, by treatment
      • 6.5.4.1.2.Brazil market size and forecast, by distribution channel
      • 6.5.4.2.Saudi Arabia
      • 6.5.4.2.1.Saudi Arabia market size and forecast, by treatment
      • 6.5.4.2.2.Saudi Arabia market size and forecast, by distribution channel
      • 6.5.4.3.South Africa
      • 6.5.4.3.1.South Africa market size and forecast, by treatment
      • 6.5.4.3.2.South Africa market size and forecast, by distribution channel
      • 6.5.4.4.Rest of LAMEA
      • 6.5.4.4.1.Rest of LAMEA market size and forecast, by treatment
      • 6.5.4.4.2.Rest of LAMEA market size and forecast, by distribution channel

CHAPTER 7:COMPANY PROFILES

  • 7.1.AMGEN INC.
    • 7.1.1.Company overview
    • 7.1.2.Company snapshot
    • 7.1.3.Operating business segments
    • 7.1.4.Product portfolio
    • 7.1.5.Business performance
    • 7.1.6.Key strategic moves and developments
  • 7.2.BEYONDSPRING INC.
    • 7.2.1.Company overview
    • 7.2.2.Company snapshot
    • 7.2.3.Product portfolio
    • 7.2.4.Business performance
    • 7.2.5.Key strategic moves and developments
  • 7.3.CELLERANT THERAPEUTICS, INC.
    • 7.3.1.Company overview
    • 7.3.2.Company snapshot
    • 7.3.3.Product portfolio
    • 7.3.4.Key strategic moves and developments
  • 7.4.KYOWA KIRIN
    • 7.4.1.Company overview
    • 7.4.2.Company snapshot
    • 7.4.3.Operating business segments
    • 7.4.4.Product portfolio
    • 7.4.5.Business performance
  • 7.5.MYLAN N.V.
    • 7.5.1.Company overview
    • 7.5.2.Company snapshot
    • 7.5.3.Operating business segments
    • 7.5.4.Product portfolio
    • 7.5.5.Business performance
    • 7.5.6.Key strategic moves and developments
  • 7.6.NOVARTIS AG
    • 7.6.1.Company overview
    • 7.6.2.Company snapshot
    • 7.6.3.Operating business segments
    • 7.6.4.Product portfolio
    • 7.6.5.Business performance
  • 7.7.PARTNER THERAPEUTICS, INC.
    • 7.7.1.Company overview
    • 7.7.2.Company snapshot
    • 7.7.3.Product portfolio
    • 7.7.4.Key strategic moves and developments
  • 7.8.PFIZER INC.
    • 7.8.1.Company overview
    • 7.8.2.Company snapshot
    • 7.8.3.Operating business segments
    • 7.8.4.Product portfolio
    • 7.8.5.Business performance
    • 7.8.6.Key strategic moves and developments
  • 7.9.SPECTRUM PHARMACEUTICALS, INC.
    • 7.9.1.Company overview
    • 7.9.2.Company snapshot
    • 7.9.3.Operating business segments
    • 7.9.4.Product portfolio
    • 7.9.5.Business performance
  • 7.10.TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 7.10.1.Company overview
    • 7.10.2.Company snapshot
    • 7.10.3.Operating business segments
    • 7.10.4.Product portfolio
    • 7.10.5.Business performance
  • 7.11.COHERUS BIOSCIENCES, INC.
    • 7.11.1.Company overview
    • 7.11.2.Company snapshot
    • 7.11.3.Operating business segments
    • 7.11.4.Product portfolio
    • 7.11.5.Business performance
    • 7.11.6.Key strategic moves and developments

LIST OF TABLES

  • TABLE 01.DOSAGE AND ADMINISTRATION OF CSFS
  • TABLE 02.GLOBAL NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027 ($MILLION)
  • TABLE 03.GLOBAL NEUTROPENIA TREATMENT MARKET FOR COLONY-STIMULATING FACTOR, BY REGION, 2019-2027($MILLION)
  • TABLE 04.GLOBAL NEUTROPENIA TREATMENT MARKET FOR ANTIBIOTICS, BY REGION, 2019-2027($MILLION)
  • TABLE 05.GLOBAL NEUTROPENIA TREATMENT MARKET FOR ANTIFUNGAL, BY REGION, 2019-2027($MILLION)
  • TABLE 06.GLOBAL NEUTROPENIA TREATMENT MARKET FOR ANTIVIRALS, BY REGION, 2019-2027($MILLION)
  • TABLE 07.GLOBAL NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 08.GLOBAL NEUTROPENIA TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2019-2027($MILLION)
  • TABLE 09.GLOBAL NEUTROPENIA TREATMENT MARKET FOR RETAIL PHARMACIES, BY REGION, 2019-2027($MILLION)
  • TABLE 10.GLOBAL NEUTROPENIA TREATMENT MARKET FOR ONLINE PHARMACIES, BY REGION, 2019-2027($MILLION)
  • TABLE 11.GLOBAL NEUTROPENIA TREATMENT MARKET, BY REGION 2019-2027, ($MILLION)
  • TABLE 12.NORTH AMERICA NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
  • TABLE 13.NORTH AMERICA NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 14.NORTH AMERICA NEUTROPENIA TREATMENT MARKET, BY COUNTRY, 2019-2027, ($MILLION)
  • TABLE 15.U.S. NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
  • TABLE 16.U.S. NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 17.CANADA NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
  • TABLE 18.CANADA NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 19.MEXICO NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
  • TABLE 20.MEXICO NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 21.EUROPE NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
  • TABLE 22.EUROPE NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 23.EUROPE NEUTROPENIA TREATMENT MARKET, BY COUNTRY, 2019-2027, ($MILLION)
  • TABLE 24.GERMANY NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
  • TABLE 25.GERMANY NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 26.FRANCE NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
  • TABLE 27.FRANCE NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 28.UK NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
  • TABLE 29.UK NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 30.ITALY NEUTROPENIA TREATMENT MARKET, BY TREATMETN, 2019-2027, ($MILLION)
  • TABLE 31.ITALY NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 32.SPAIN NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
  • TABLE 33.SPAIN NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 34.REST OF EUROPE NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
  • TABLE 35.REST OF EUROPE NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 36.ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
  • TABLE 37.ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 38.ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET, BY COUNTRY, 2019-2027, ($MILLION)
  • TABLE 39.JAPAN NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
  • TABLE 40.JAPAN NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 41.CHINA NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
  • TABLE 42.CHINA NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 43.AUSTRALIA NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
  • TABLE 44.AUSTRALIA NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 45.INDIA NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
  • TABLE 46.INDIA NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 47.REST OF ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
  • TABLE 48.REST OF ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 49.LAMEA NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
  • TABLE 50.LAMEA NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 51.LAMEA NEUTROPENIA TREATMENT MARKET, BY COUNTRY, 2019-2027, ($MILLION)
  • TABLE 52.BRAZIL NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
  • TABLE 53.BRAZIL NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 54.SAUDI ARABIA NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
  • TABLE 55.SAUDI ARABIA NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 56.SOUTH AFRICA NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
  • TABLE 57.SOUTH AFRICA NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 58.REST OF LAMEA NEUTROPENIA TREATMENT MARKET, BY TREATMENT, 2019-2027, ($MILLION)
  • TABLE 59.REST OF LAMEA NEUTROPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027, ($MILLION)
  • TABLE 60.AMGEN: COMPANY SNAPSHOT
  • TABLE 61.AMGEN: OPERATING SEGMENTS
  • TABLE 62.AMGEN: PRODUCT PORTFOLIO
  • TABLE 63.AMGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 64.BEYONDSPRING : COMPANY SNAPSHOT
  • TABLE 65.BEYONDSPRING : PRODUCT PORTFOLIO
  • TABLE 66.BEYONDSPRING : KEY STRATEGIC MOVES AND DEVELOPMENT
  • TABLE 67.CELLERANT THERAPEUTICS : COMPANY SNAPSHOT
  • TABLE 68.CELLERANT THERAPEUTICS : PRODUCT PORTFOLIO
  • TABLE 69.CELLERANT THERAPEUTICS : KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 70.KYOWA KIRIN : COMPANY SNAPSHOT
  • TABLE 71.KYOWA KIRIN: OPERATING SEGMENTS
  • TABLE 72.KYOWA KIRIN : PRODUCT PORTFOLIO
  • TABLE 73.MYLAN: COMPANY SNAPSHOT
  • TABLE 74.MYLAN: OPERATING SEGMENTS
  • TABLE 75.MYLAN: PRODUCT PORTFOLIO
  • TABLE 76.MYLAN : KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 77.NOVARTIS: COMPANY SNAPSHOT
  • TABLE 78.NOVARTIS: OPERATING SEGMENTS
  • TABLE 79.NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 80.PARTNER THERAPEUTICS : COMPANY SNAPSHOT
  • TABLE 81.PARTNER THERAPEUTICS : PRODUCT PORTFOLIO
  • TABLE 82.PARTNER THERAPEUTICS : KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 83.PFIZER : COMPANY SNAPSHOT
  • TABLE 84.PFIZER : OPERATING SEGMENTS
  • TABLE 85.PFIZER : PRODUCT PORTFOLIO
  • TABLE 86.PFIZER : KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 87.SPECTRUM PHARMACEUTICALS : COMPANY SNAPSHOT
  • TABLE 88.SPECTRUM PHARMACEUTICALS : OPERATING SEGMENTS
  • TABLE 89.SPECTRUM PHARMACEUTICALS : PRODUCT PORTFOLIO
  • TABLE 90.TEVA: COMPANY SNAPSHOT
  • TABLE 91.TEVA: OPERATING SEGMENTS
  • TABLE 92.TEVA: PRODUCT PORTFOLIO
  • TABLE 93.COHERUS BIOSCIENCES: COMPANY SNAPSHOT
  • TABLE 94.COHERUS BIOSCIENCES : OPERATING SEGMENTS
  • TABLE 95.COHERUS BIOSCIENCES: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.SEGMENTATION OF GLOBAL NEUTROPENIA TREATMENT MARKET
  • FIGURE 02.PIPELINE ANALYSIS, BY COUNTRY
  • FIGURE 03.PIPELINE ANALYSIS, BY PHASES
  • FIGURE 04.PIPELINE ANALYSIS, BY YEAR
  • FIGURE 05.TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 06.TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 07.TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 08.TOP PLAYER POSTIONING, 2019
  • FIGURE 09.HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 10.LOW BARGAINING POWER OF BUYERS
  • FIGURE 11.MODERATE THREAT OF SUBSTITUTION
  • FIGURE 12.MODERATE THREAT OF NEW ENTRANT
  • FIGURE 13.MODERATE COMPETITIVE RIVALRY
  • FIGURE 14.GLOBAL NEUTROPENIA TREATMENT MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF NEUTROPENIA TREATMENT MARKET FOR COLONY-STIMULATING FACTOR, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF NEUTROPENIA TREATMENT MARKET FOR ANTIBIOTICS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF NEUTROPENIA MARKET FOR ANTIFUNGAL, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF NEUTROPENIA TREATMENT MARKET FOR ANTIVIRALS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF GLOBAL NEUTROPENIA TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF GLOBAL NEUTROPENIA TREATMENT MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF GLOBAL NEUTROPENIA TREATMENT MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 22.U.S. NEUTROPENIA MARKET, 2020-2027 ($MILLION)
  • FIGURE 23.AMGEN: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 24.AMGEN : REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 25.KYOWA KIRIN : NET SALES, 2017-2019 ($MILLION)
  • FIGURE 26.KYOWA KIRIN : REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 27.KYOWA KIRIN : REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 28.MYLAN: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 29.MYLAN: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 30.NOVARTIS: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 31.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 32.NOVARTIS: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 33.PFIZER : NET SALES, 2017-2019 ($MILLION)
  • FIGURE 34.PFIZER : REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 35.PFIZER: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 36.SPECTRUM PHARMACEUTICALS : NET SALES, 2016-2018 ($MILLION)
  • FIGURE 37.SPECTRUM PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2018 (%)
  • FIGURE 38.TEVA: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 39.TEVA: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 40.COHERUS BIOSCIENCES : NET SALES, 2017-2019 ($MILLION)